Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
Amir Hossein Daneshmanesh(Karolinska University Hospital), H Mellstedt(Karolinska University Hospital), Mohammad Mehdi Akhondi(The University of Texas Southwestern Medical Center), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Mahmood Jeddi‐Tehrani(Academic Center for Education, Culture and Research), Ali Ahmad Bayat(Academic Center for Education, Culture and Research), Abdul Salam Khan(Karolinska University Hospital), AR Mahmoudi(Academic Center for Education, Culture and Research), Reza Hadavi(Academic Center for Education, Culture and Research), Fazel Shokri(Tehran University of Medical Sciences), Roya Ghods(Academic Center for Education, Culture and Research), Hodjattallah Rabbani(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital)
Cited by 104
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312